Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101

Conclusion: These results reveal a novel approach to enhance anti-PD-1 therapy with VDAs + VEGF/VEGFR2 inhibitors in HCC.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Xin Bao, Na Shen, Yan Lou, Haiyang Yu, Yue Wang, Linlin Liu, Zhaohui Tang, Xuesi Chen Tags: Research Paper Source Type: research